Merck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda Challenges
Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...
Hosted on MSN8d
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...
Insider Monkey7d
10 Best Russell 2000 Stocks to Invest in According to Analysts
This expanded coverage addresses a critical gap in the existing PCV market, where existing vaccines such as Pfizer’s Prevnar 20 and Merck’s Capvaxive (21-valent) cover a significant but not ...
FiercePharma9d
In PAHO-backed access initiative, Argentina's Sinergium Biotech to locally produce Pfizer's Prevnar 20
Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...
Investing22d
The 2025 Dogs of the Dow: 10 High-Yield Blue Chips
However, Merck may have to contend with Inflation ... Traction on invasive pneumococcal disease and pneumococcal pneumonia vaccine Capvaxive, which the CDC’s Advisory Committee on Immunization ...
pharmaphorum2d
FDA says yes to MSD’s 21-valent adult pneumococcal jab
With Capvaxive, MSD (known as Merck & Co in the US and Canada) is aiming to carve out a niche in the over-50s, positioning it as the go-to vaccine used to prevent invasive pneumococcal disease ...
Forbes21d
Big Blue Chip Dividends? Try These ‘Dogs’ Up To 6.8%
However, Merck may have to contend with Inflation ... Traction on invasive pneumococcal disease and pneumococcal pneumonia vaccine Capvaxive, which the CDC’s Advisory Committee on Immunization ...